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Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: 
A Prospective Analysis in Patients with Colorectal Cancer
Introduction
Currently, standard therapy for patients with advanced colorectal
cancer (CRC) is combination chemotherapy with fluoropyrimidine,
sometimes modulated by folinic acid (FA), plus irinotecan or oxali-
platin (1). Oxaliplatin is a platinum analogue that blocks DNA
replication and transcription (2). This agent is particularly attractive
because of its activity against cisplatin-resistant colon cancer cell lines
(3). Oxaliplatin and infusional 5-fluorouracil (5-FU) with or without
FA, namely FOLFOX, has been reported to be active and compara-
tively safe, and is now recommended as the standard first-line
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Purpose
Oxaliplatin-induced chronic peripheral neurotoxicity (OXCPN) manifests as a loss of sensation
and dysesthesia in the distal extremities, which may impair daily activities and increase in
incidence with the amount of oxaliplatin delivered. The variation in the reported incidence and
severity of OXCPN may be a consequence of differences in the baseline characteristics of
patients.
Materials and Methods
This was a prospective study (ClinicalTrials.gov, NCT00977717) in which OXCPN was
recorded for all consecutive colon cancer patients treated at Samsung Medical Center
(Seoul, Korea) with oxaliplatin-based combination chemotherapy. The primary endpoint was
the incidence of severe OXCPN (grade 2 lasting for ＞7 days, or grade 3). The association of
severe OXCPN and pretreatment parameters was evaluated using a multivariate regression
model.
Results
Between Jan 2008 and Feb 2010, 100 patients treated with adjuvant folinic acid/fluorouracil
plus oxaliplatin (FOLFOX) and 266 patients treated with capecitabine plus oxaliplatin (XELOX)
or FOLFOX for advanced disease were registered into our study. The median cumulative
dose of oxaliplatin was 796 mg/m
2(range, 85 to 1,583 mg/m
2). Severe OXCPN was observed in
126 (34%) patients. Overall, 43 patients discontinued chemotherapy due to toxicity: 23 without
severe OXCPN and 20 with severe OXCPN. In univariate analysis, severe OXCPN was
frequently observed in patients with age ≥55 years (p＜0.01), stage II or III (p＜0.01),
adjuvant setting (p=0.01), FOLFOX (p＜0.01), performance status of 0 (p=0.02), and those with
no prior chemotherapy (p＜0.01). In a multivariate regression model, the number of
chemotherapy cycles and the cumulative oxaliplatin dose were not associated with the
development of severe OXCPN.
Conclusion
We failed to find a significant association between patient characteristics at baseline and
the development of severe OXCPN after oxaliplatin-based combination chemotherapy.
Pharmacogenomic profiling using genome-wide association study in these patients is
underway.
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│ http://www.e-crt.org│chemotherapy for patients with advanced CRC (4,5), as well as in the
adjuvant setting (6). The main dose-limiting toxicity of oxaliplatin is
peripheral neuropathy, which affects 90% of all treated patients, and
which may be reversible after discontinuation of treatment (7). Oxali-
platin neurotoxicity occurs as two distinct syndromes: acute neuro-
sensory toxicity, and chronic, cumulative peripheral neurotoxicity.
Oxaliplatin-induced chronic peripheral neurotoxicity (OXCPN) mani-
fests as a loss of sensation and dysesthesia in the distal extremities,
which may impair daily activities and increase in incidence with the
amount of oxaliplatin delivered. The mechanism of cumulative
OXCPN remains unknown; however, it has been suggested that plati-
num accumulation in the dorsal root ganglion causes apoptosis of ter-
minal sensory neurons (8).
In addition to efforts to identify effective prophylactic or therapeutic
agents for OXCPN, there have been studies attempting to define
predictive markers for OXCPN. An accurate marker of OXCPN that
would provide a prediction of the incidence or severity would prove
valuable in controlling this toxicity. In the current study, we evaluated
the incidence and severity of OXCPN in order to investigate the
association of OXCPN with baseline characteristics in patients with
colon cancer.
Materials and Methods
1  Eligibility
This was a prospective study (ClinicalTrials.gov, NCT00977717), in
which the incidence and severity of OXCPN was recorded for all
consecutive colon cancer patients treated with oxaliplatin-based
combination chemotherapy. The study was designed to include 100
consecutive consenting patients who were treated with FA, 5-FU and
oxaliplatin (FOLFOX) combination chemotherapy for curatively-
resected, stage II to IV, colon cancer. At the same time, colon cancer
patients who were treated with oxaliplatin-based first-line chemo-
therapy for advanced disease were also enrolled. Other eligibility
criteria included: age 18 years or older, Eastern Cooperative Oncology
Group (ECOG) performance status of 2 or lower, no evidence of neu-
rosensory disease, resolution of all surgery-related complications, and
the absence of major organ dysfunctions. All patients were treated and
followed at Samsung Medical Center (SMC), Seoul, Korea. The nature
and purpose of the study was fully explained and discussed with each
patient, and each provided the investigators with written informed
consent before registration. This study was approved by the SMC
institutional review board.
2 Chemotherapy
In the adjuvant setting, FOLFOX began no more than 5 weeks after
surgery. Patients were treated with a modified FOLFOX regimen
which included oxaliplatin 85 mg/m
2 iv on day 1, FA 200 mg/m
2 iv on
day 1, and 5-FU 400 mg/m
2 iv bolus on day 1 followed by 2,400
mg/m
2 iv over 46 hours. Adjuvant FOLFOX was repeated every 2
weeks until recurrence, unacceptable toxicity, patient withdrawal from
the study, or a maximum of 12 cycles. A second group of patients, those
with advanced disease, were treated with oxaliplatin 130 mg/m
2 iv on
day 1 plus capecitabine 2,000 mg/m
2/day on days 1 to 14 (XELOX,
repeated every 3 weeks), or FOLFOX. Supportive care, including
administration of blood transfusions, use of hematopoietic growth
factors, antiemetics and analgesics were provided if judged appropriate
by the investigators.
3 Evaluation of neurotoxicity
Toxicity was evaluated during treatment according to criteria of the
National Cancer Institute (NCI-CTCAE) version 3 (9). FOLFOX
patients were seen every 2 weeks. For XELOX patients, clinical
adverse events and blood counts were checked on day 1 every 3
weeks. OXCPN was evaluated and graded before starting each
chemotherapy cycle. In brief, grade 1 referred to asymptomatic or mild
paresthesia, but not interfering with function. Grade 2 OXCPN was
defined as moderate paresthesia or dysesthesia interfering with
function, but not interfering with activities of daily living (ADL).
Patients with painful paresthesia interfering with ADL were regarded
as grade III. In addition to subjective assessment, a short, standardized
neurologic examination including the testing of exteroceptive sensation
in the hands and feet, and testing of proprioceptive sensation was done.
In case of grade 2 or 3 OXCPN, chemotherapy was delayed up to a
maximum of 2 weeks. Dose modification was done based on hema-
tologic parameters and the degree of non-hematologic toxicity seen
during the preceding cycle. In particular, oxaliplatin was reduced in
cases of severe OXCPN. In cases of persistent (14 days or longer)
grade 2 OXCPN or functional impairment, oxaliplatin was omitted
from the regimen until recovery.
4 Statistical considerations
The primary endpoint of the current study was the incidence of
severe OXCPN during the treatment period. Severe OXCPN was
defined in the protocol as prolonged (7 days or longer) grade 2, or
grade 3 of any duration. The time to occurrence of severe OXCPN was
the secondary endpoint and was calculated from the date of initiation of
therapy to the day on which the toxicity was first noticed. Comparisons
were made using Mann-Whitney U tests for non-normally distributed
data and paired t-tests for normally distributed data. The Chi-square test
was used for comparison of categorical variables. To examine the
impact of clinical and treatment variables on the incidence of severe
OXCPN, multiple logistic regression models were used. Covariates
included age, gender, ECOG performance status (0-1 vs. 2), therapy
aim (adjuvant vs. palliative), stage (II or III vs. IV), body surface area,
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creatinine clearance, and chemotherapy regimens (FOLFOX vs.
XELOX). The backward selection procedure with removal criterion p
＞0.10 based on a chi-square test was used to identify significant
parameters. In addition, factors affecting the time to occurrence of
severe OXCPN were evaluated using the above covariates plus
chemotherapy duration and cumulative dose of oxaliplatin. All p-
values were two-sided, with p＜0.05 indicating statistical significance.
Results
Between Jan 2008 and Feb 2010, a total of 100 adjuvant patients and
266 palliative patients were enrolled into the study. Detailed cha-
racteristics of the patients are listed in Table 1. Two hundred and
eighty-seven patients were treated with biweekly FOLFOX, while 79
received 3-weekly XELOX. The median number of chemotherapy
cycles administered to patients was 12 (range, 1 to 22) and the median
treatment duration was 5.5 months (95% confidence interval [CI], 5.4
to 5.6 months). Patients on adjuvant FOLFOX received a median of
935 mg/m
2 of oxaliplatin (range, 510 to 1,020 mg/m
2); those in the
palliative setting received a median of 899 mg/m
2 (range, 500 to 1,583
mg/m
2).
In 14 patients (3.8%), data for OXCPN were not available because
they received only one cycle of therapy or were lost to follow-up.
Overall, 299 (85%) patients experienced OXCPN during treatment.
The maximum grade of OXCPN was 1 in 163 patients; 2 in 123 pa-
tients; and 3 in 13 patients. The time to the development of OXCPN
was clearly dependent on the duration of chemotherapy and the cumu-
lative oxaliplatin dose: 42% and 85% of patients experienced OXCPN
of any grade after 3 months and 6 months, respectively.
Severe OXCPN was observed in 126 (34%) patients. Overall, 43
patients discontinued chemotherapy due to toxicity: 23 patients without
severe OXCPN; and 20 with severe OXCPN (17 prolonged grade 2
OXCPN, 3 grade 3). Management of all patients with severe OXCPN
was conservative. Short-acting analgesics and/or oral gabapentin were
recommended and, in some patients, oral or transdermal narcotics were
prescribed. Oxaliplatin dose reduction and treatment with analgesics
resulted in transient improvement, but only one patient showed
All patients (n=366) Adjuvant (n=100) Palliative (n=266)
Age (yr)
Median (range) 56 (24-75) 56 (24-72) 55 (27-75)
Gender
Male 201 55 146
Female 165 45 120
Stage
II 1 1 0
III 82 82 0
IV 283 17 266
Prior chemotherapy
5-fluorouracil±folinic acid 10 0 10
Capecitabine 16 0 16
Adjuvant FOLFOX* 14 0 14
Body surface area (m
2) 
Median (range) 1.63 (1.34-2.01) 1.66 (1.34-2.01) 1.62 (1.34-2.01)
Creatinine clearance (mg/mL)
Median (range) 75.8 (47.3-179.6) 82.1 (47.3-179.6) 74.2 (47.7-166.8)
Presence of comorbid illness
� 75 22 53
ECOG
�performance status
0 243 62 181
1 121 38 83
22 0 2
Chemotherapy regimen
§
FOLFOX 287 100 187
XELOX
‖ 79 0 79
Table 1. Patient characteristics
*folinic acid, 5-fluorouracil and oxaliplatin, 
�comorbidities included diabetes (n=52), hypertension and/or history of cardiovascular disease (n=23), viral hepatitis B (n=11) and history
of other malignancies (n=2), 
�Eastern Cooperative Oncology Group, 
§ in palliative setting, 23 patients were treated with bevacizumab concomitantly with FOLFOX or XELOX, 
‖ca-
pecitabine and oxaliplatin.sustained improvement of severe OXCPN.
Ten baseline parameters were subjected to univariate analysis for
their ability to predict severe OXCPN. The following parameters were
associated with the development of severe OXCPN (Table 2): age 55
years or older (p＜0.01); stage II or III (p＜0.01); adjuvant chemo-
therapy (p=0.01); FOLFOX (p＜0.01); performance status of 0
(p=0.02); no prior chemotherapy (p＜0.01). Gender, the presence of
comorbid illness, body surface area, and creatinine clearance was not a
significant predictor of severe OXCPN.
These six parameters with univariate significance were entered into
a multivariate logistic regression model. These parameters were
selected because of their statistical significance in univariate analysis
and their perceived clinical relevance. The independent association
with severe OXCPN was examined in a backward selection procedure.
Two baseline parameters were determined to have independent
significance: stage II or III (vs. IV); and FOLFOX (vs. XELOX).
Interaction between these two predictive parameters was then
considered. A two-way interaction between stage and chemotherapy
regimen was found to be highly significant (p＜0.01). A model
containing an interaction term between stage and regimen no longer
showed these two parameters as being significant, and the interaction
was eliminated by deleting stage from the model.
Fig. 1 shows time to occurrence of severe OXCPN by chemo-
therapy regimen. When, for exploratory purposes, we compared the
cumulative hazard rates between patients who received FOLFOX
versus XELOX, the chance of developing severe OXCPN was
significantly higher in those receiving FOLFOX (p=0.03). The cumu-
lative hazard of developing severe OXCPN increased above 10% after
1.5 months, and increased up to 30% at 4 months. However, a multi-
variate model containing chemotherapy regimen and the cumulative
oxaliplatin dose revealed that neither biweekly FOLFOX (odds ratio,
1.60; 95% CI, 0.88 to 4.93; p=0.09) nor cumulative oxaliplatin dose
Cancer Res Treat. 2010;42(4):185-190
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Total (n)
Univariate Multivariate
No.* (%) p-value Odds ratio 95% CI p-value
Age (yr) <0.01 0.54
＜55   189 55 (29) 1
≥55   177 71 (40) 1.29 0.57-.90
Gender  0.22
Male  201 68 (34)
Female  165 58 (35)
Stage  <0.01 0.04
II or III  83 40 (48) 1
IV  283 86 (30) 0.51 0.28-0.95
Therapy aim  0.01 0.42
Adjuvant  100 43 (43) 1
Palliative  266 83 (31) 0.81 0.48-1.36
Chemotherapy  <0.01 < 0.01
FOLFOX
� 287 111 (39) 1
XELOX
� 79 15 (19) 0.23 0.10-0.56
Performance status  0.02 0.10
0  243 90 (37) 1
1 or 2  123 36 (29) 0.64 0.37-1.10
Prior chemotherapy  <0.01 0.10
No  326 111 (34) 1
Yes  40 15 (38) 0.49 0.22-1.13
Comorbidity  0.79
None  291 96 (33)
Present  75 30 (40)
Body surface area (m
2) 0.15
＜1.6   167 64 (38)
≥1.6    199 62 (31)
Creatinine clearance (mL/min) 0.38
＜75   178 66 (37)
≥75 188    60 (32)
Table 2. Association of the incidence of severe oxaliplatin-induced chronic peripheral neurotoxicity and baseline characteristics
*number of patients with severe oxaliplatin-induced chronic peripheral neurotoxicity, 
�folinic acid, 5-fluorouracil and oxaliplatin, 
�capecitabine and oxaliplatin.(odds ratio, 1.27; 95% CI, 0.59 to 2.88; p=0.51) had independent
adverse significance.
Discussion
Oxaliplatin is the standard of treatment in conjunction with 5-FU/FA
for locally-advanced and metastatic colon cancer. OXCPN is initially
mild in severity and merely a bothersome side effect of oxaliplatin.
However, it can substantially reduce quality of life. Importantly,
OXCPN, and not tumor progression, is often the cause of chemo-
therapy discontinuation. Numerous potential neuroprotective agents
have been tested against OXCPN, such as carbamazepine, gabapentin,
as have supplements such as intravenous calcium or magnesium (10).
However, to date, efforts to establish a neuroprotective agent against
OXCPN have been unsuccessful. Once OXCPN has developed,
treatment of severe OXCPN includes only conservative measures,
such as oxaliplatin dose reduction, the avoidance of cold, or analgesics.
The risk of developing OXCPN may be related to treatment
schedule, dose of oxaliplatin, cumulative dose, time of infusion and
pre-existing peripheral neuropathy (11). Although reports to date show
that an association of prolonged use of oxaliplatin and development of
OXCPN is likely, the true incidence and risk factors of severe OXCPN
are unknown. Therefore, we attempted to evaluate severe OXCPN
prospectively in consecutive patients with colon cancer treated with
oxaliplatin-based chemotherapy.
The incidence of OXCPN in patients treated with FOLFOX or
XELOX was 82%, and severe (prolonged grade 2 or grade 3) OXCPN
was observed in 34% of patients. Only chemotherapy regimen
(biweekly FOLFOX) was an independent risk factor for severe
OXCPN. Our analyses indicated that more frequent exposure to
oxaliplatin, regardless of the dose, is the most significant risk factor for
the development of severe OXCPN.
It is of note that the difference in the hazard of developing severe
OXCPN was not related to the cumulative oxaliplatin dose or treat-
ment duration. The finding is rather unexpected because previous re-
ports suggested that OXCPN develops progressively as the cumulative
oxaliplatin dose increases (8). One possible explanation is that the
grading of OXCPN was based on subjective and clinical examinations.
Despite a number of comprehensive toxicity scales, accurate grading of
OXCPN still represents a matter of controversy, mainly due to the fact
that there are variations in interpreting clinical aspects, which leads to
poor reliability. Physician-based assessments, such as the NCI-CTCAE
neuropathy score that was used in the current study, require patient
cooperation and physician training. Although quantitative tests of
neuropathy, including electrophysiological measures, are available
(12), they are not routinely used to make treatment decisions for
OXCPN (13). Currently, a widely accepted, and validated, grading
system of OXCPN is lacking. Furthermore, one may argue that this
study represents only a small group of patients with colon cancer.
However, the strength of the current study lies in a uniform patient
population and the prospective design. All patients were treated with
standardized FOLFOX or XELOX regimens for their colon cancer,
and chemotherapy-related symptoms were absent in most of the
patients before study entry.
Another explanation for the current results is that the clinical
parameters, although clinically meaningful for predicting the incidence
of OXCPN overall, might not have a defined role as a predictive
marker of severe OXCPN. Patients treated with anticancer chemo-
therapy exhibit variation, both in terms of tumor response and in the in-
cidence or severity of toxicity. The etiology of this variation is mul-
tifactorial with genetic factors likely contributing to a significant extent.
Pharmacogenetic and genomic studies can be used to identify the
genetic variants that contribute to the variation in susceptibility to
chemotherapy-induced activity and toxicity (14). The traditional ap-
proach of pharmacogenomic studies has been the candidate gene ap-
proach, in which a gene or pathway is identified as potentially im-
portant based on literature evidence and then subjected to further study.
Oxaliplatin is metabolized via the conjugation of a platinum-diami-
nocyclohexane metabolite to glutathione. This reaction is catalyzed by
the enzyme glutathione-S-transferase (GST), of which the P1 (GSTP1)
subclass of this enzyme is highly expressed in intestine (7). Ruzzo et al.
(15) reported that the incidence of oxaliplatin neuropathy was higher in
Val/Val genotype patients, whereas another study reported the opposite
(16). Gamelin et al. (17) did a study to find genetic variations involving
oxalate metabolism and the glutathione cycle, but failed to prove an
association between GSTP1 and oxaliplatin neuropathy. While studies
are beginning to point to some potential pharmacogenomic markers of
oxaliplatin neuropathy, they have not yielded conclusive findings that
have allowed for the identification of patients at risk of the toxicity.
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*
Fig. 1. Cumulative hazard of developing severe oxaliplatin-induced
chronic peripheral neurotoxicity according to chemotherapy re-
gimens. *folinic acid, 5-fluorouracil and oxaliplatin, 
�capecitabine
and oxaliplatin.Conclusion
We failed to find baseline clinical parameters that were significant
predictors of the development of severe OXCPN in colon cancer
patients treated with oxaliplatin-based combination chemotherapy. A
genome-wide polymorphism study is underway to describe variations
between patients and to investigate a possible association with the
development of severe OXCPN (18).
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